US-based biopharmaceutical company Celladon closed a $43 equity round on Wednesday led by Pfizer Ventures, the corporate venturing fund for pharmaceutical corporation Pfizer.

Two other corporate venturing funds for pharma companies – Novartis Venture Funds, and Johnson & Johnson Development Corporation – also participated in the round, as did life science venture funds Hambrecht & Quist Healthcare/Life Sciences Investors and Lundbeckfond Ventures, and venture capital firms Venrock, Enterprise Partners and GBS Venture Partners.

The cash will be used to advance…